StemCyte-KY announced on March 4 the signing of a Memorandum of Understanding (MOU) with a major international medical group in China. The partnership targets the licensing and commercialization of REGENECYTE®, its proprietary umbilical cord blood cell therapy, specifically leveraging the policy advantages of the Hainan Boao Lecheng International Medical Tourism Pilot Zone.
Read more
